Human DPPIV/CD26 Alexa Fluor® 405-conjugated Antibody Summary
Accession # Q53TN1
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Preparation and Storage
DPPIV/CD26 (EC 18.104.22.168) is a serine exopeptidase that releases Xaa-Pro dipeptides from the N-terminus of oligo- and polypeptides (1, 2). It is a type II membrane protein consisting of a short cytoplasmic tail, a transmembrane domain, and a long extracellular domain (3‑5). The extracellular domain contains glycosylation sites, a cysteine-rich region and the catalytic active site (Ser, Asp and His charge relay system). The amino acid sequence of the mouse DPPIV/CD26 extracellular domain is 84% and 91% identical to the human and rat counterparts, respectively. In the native state, DPPIV/CD26 is present as a noncovalently linked homodimer on the cell surface of a variety of cell types. The soluble form is also detectable in human serum and other body fluids, the levels of which may have clinical significance in patients with cancer, liver and kidney diseases, and depression. DPPIV/CD26 plays an important role in many biological and pathological processes. It functions as T cell-activating molecule (THAM). It serves as a cofactor for entry of HIV in CD4+ cells (6). It binds adenosine deaminase, the deficiency of which causes severe combined immunodeficiency disease in humans (7). It cleaves chemokines such as stromal-cell-derived factor 1 alpha and macrophage-derived chemokine (8, 9). It degrades peptide hormones such as glucagon (10). It truncates procalcitonin, a marker for systemic bacterial infections with elevated levels detected in patients with thermal injury, sepsis and severe infection, and in children with bacterial meningitis (11).
- Misumi and Ikehara (1998) in Handbook of Proteolytic Enzymes. Barrett, et al. (eds) San Diego: Academic Press, p. 378.
- Ikehara, et al. (1994) Methods Enzymol. 244:215.
- Marguet, et al. (1992) J. Biol. Chem. 267:2200.
- Bernard, et al. (1994) Biochemistry 33:15204.
- Viver, et al. (1991) J. Immunol. 147:447.
- Callebaut, et al. (1993) Science 262:2045.
- Kameoka, et al. (1993) Science 261:466.
- Ohtsuki, et al. (1998) FEBS Lett. 431:236.
- Proost, et al. (1999) J. Biol. Chem. 274:3988.
- Hinke, et al. (2000) J. Biol. Chem. 275:3827.
- Wrenger, et al. (2000) FEBS Lett. 466:155.
Citation for Human DPPIV/CD26 Alexa Fluor® 405-conjugated Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
1 Citation: Showing 1 - 1
Synergistic cytotoxic activity of cannabinoids from cannabis sativa against cutaneous T-cell lymphoma (CTCL) in-vitro and ex-vivo
Authors: M Mazuz, A Tiroler, L Moyal, E Hodak, S Nadarajan, AC Vinayaka, B Gorovitz-H, I Lubin, A Drori, G Drori, OV Cauwenberg, A Faigenboim, D Namdar, I Amitay-Lai, H Koltai
Sample Types: Whole Cells
Applications: Flow Cytometry
No product specific FAQs exist for this product, however you mayView all Antibody FAQs
Reviews for Human DPPIV/CD26 Alexa Fluor® 405-conjugated Antibody
There are currently no reviews for this product. Be the first to review Human DPPIV/CD26 Alexa Fluor® 405-conjugated Antibody and earn rewards!
Have you used Human DPPIV/CD26 Alexa Fluor® 405-conjugated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image